The pathogenic TH17.1 cells, primarily present in RA and CD, secrete only small amounts of IL-17A and IL-17F, which is why monotherapy with an IL-17A antibody shows only moderate effects in these clinical conditions [13]. Here, IL17A is linked to rheumatoid arthritis.